

INNOVUS PHARMACEUTICALS, INC.

Form 8-K

March 22, 2017

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 21, 2017

INNOVUS PHARMACEUTICALS, INC.  
(Exact name of registrant as specified in its charter)

Nevada	000-52991	90-0814124
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

9171 Towne Centre Drive, Suite 440, San Diego, CA	92122
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: (858) 964-5123

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

In this report, “Innovus Pharmaceuticals,” “Innovus Pharma,” “the Company,” “we,” “us” and “our” refer to Innovus Pharmaceuticals, Inc., and/or one or more of our wholly-owned subsidiaries, unless the context otherwise provides. Innovus Pharma® is a registered service mark of Innovus Pharmaceuticals, Inc.

Item 7.01 – Regulation FD Disclosure

Item 8.01 – Other Events

On March 22, 2017, the Company issued a press release reporting that the Company has repaid all of its outstanding convertible notes. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 -- Financial Statements and Exhibits

(d) Exhibits

Exhibit Number	Description
99.1	Press release issued March 22, 2017, reporting that the Company has repaid all of its outstanding convertible notes.

SIGNATURES

Pursuant to  
the  
requirements  
of the  
Securities  
Exchange  
Act of 1934,  
the  
Registrant  
has duly  
caused this  
Report to be  
signed on its  
behalf by the  
undersigned  
hereunto duly  
authorized.

INNOVUS PHARMACEUTICALS, INC

Date: March 22, 2017 By: /s/ ROBERT E. HOFFMAN  
Robert E. Hoffman  
Executive Vice President, Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release issued March 22, 2017, reporting that the Company has repaid all of its outstanding convertible notes.